FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891679268> ?p ?o ?g. }

• W2891679268 abstract "Thromboembolic disorders are the major cause of death and disability worldwide. Anticoagulants are the mainstay in the prevention and treatment of thromboembolic diseases. However, almost all the currently available anticoagulants cause therapy-related haemorrhages as a side effect. In the recent years, FXIIa was highlighted as an attractive target for the development of new anticoagulant drugs with low rates of therapy-related haemorrhages. In this work, the development of a new class of chemical inhibitors as potent and selective nonpeptidic inhibitors of FXIIa has been described.The structural information of FXIIa is not as prevalent as that of FXa and thrombin. Therefore, the 3D-structure of FXIIa in the active conformation was elaborated by homology studies. Given the structural and functional similarities between FXIIa and FXa, rivaroxaban, a known FXa inhibitor, was used as a starting point for this project.Using a combination of medicinal chemistry and computational chemistry strategies, rivaroxaban analogues with acceptable inhibitory activity against FXIIa were readily identified. However, these early analogues showed poor selectivity profiles. Two important structural features of FXIIa inhibitors have been extracted from iterative make-test cycles, an amine derivative at the P1-position and piperazine derivative at the P4-position. Compound 4-(aminomethyl)-N-({(5S)-2-oxo-3-[4-(piperazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)benzamide (v8) was synthesised with piperazine at the P4-position and 4-(aminomethyl)benzoyl at the P1-position. It was found that compound v8 inhibited FXIIa activity in a chromogenic biochemical assay with an IC50 value of 0.18 ± 0.1 μM. Interestingly, this compound was found to be 72-fold more potent against FXIIa than FXa. In another set of compounds, compound 4-carbamimidoyl-N-({(5S)-2-oxo-3-[4-(piperazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)benzamide (z8) was synthesised with a 4-carbamimidoylbenzoyl group at the p1-position and piperazine at the P4-position. This compound was 14-fold more potent against FXIIa than FXa. Also, this compound was 1.5-fold more potent against FXIIa than compound v8, but it was less selective to FXIIa. In a further structural refinement, 4-(aminomethyl)benzoyl was replaced with a 4-carbamoylbenzoyl at the P1-position. This afforded compound N1-({(5S)-2-oxo-3-[4-(piperazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)benzene-1,4-dicarboxamide (w8) with an IC50 against FXIIa of 0.16 ± 0.05 µM, but with significant improvement in the selectivity factor to FXIIa (selectivity factor = 206) compared to compounds z8 and v8. Docking studies showed that FXa inhibitory activity depends mainly on hydrophobic interactions at the S1- and S4-subpockets. Compounds deprived of the Cl-π interactions at the S1-pocket and/or π-π stacking at the S4-pocket were almost always less potent against FXa than compounds that can make such interactions. However, the inhibitory potency against FXIIa depends mainly on electrostatic interaction in the S1- and S4-pockets especially with Asp189 residue at the bottom of the S1-pocket." @default.
• W2891679268 created "2018-09-27" @default.
• W2891679268 creator A5062980919 @default.
• W2891679268 date "2018-07-20" @default.
• W2891679268 modified "2023-09-23" @default.
• W2891679268 title "Design, synthesis, and characterisation of small molecule inhibitors of the coagulation factor XIIa (FXIIa)" @default.
• W2891679268 hasPublicationYear "2018" @default.
• W2891679268 type Work @default.
• W2891679268 sameAs 2891679268 @default.
• W2891679268 citedByCount "0" @default.
• W2891679268 crossrefType "dissertation" @default.
• W2891679268 hasAuthorship W2891679268A5062980919 @default.
• W2891679268 hasConcept C178790620 @default.
• W2891679268 hasConcept C185592680 @default.
• W2891679268 hasConcept C21951064 @default.
• W2891679268 hasConcept C2776201271 @default.
• W2891679268 hasConcept C71240020 @default.
• W2891679268 hasConcept C71924100 @default.
• W2891679268 hasConcept C98274493 @default.
• W2891679268 hasConceptScore W2891679268C178790620 @default.
• W2891679268 hasConceptScore W2891679268C185592680 @default.
• W2891679268 hasConceptScore W2891679268C21951064 @default.
• W2891679268 hasConceptScore W2891679268C2776201271 @default.
• W2891679268 hasConceptScore W2891679268C71240020 @default.
• W2891679268 hasConceptScore W2891679268C71924100 @default.
• W2891679268 hasConceptScore W2891679268C98274493 @default.
• W2891679268 hasLocation W28916792681 @default.
• W2891679268 hasOpenAccess W2891679268 @default.
• W2891679268 hasPrimaryLocation W28916792681 @default.
• W2891679268 hasRelatedWork W1999251997 @default.
• W2891679268 hasRelatedWork W2003325869 @default.
• W2891679268 hasRelatedWork W2018237950 @default.
• W2891679268 hasRelatedWork W2022666232 @default.
• W2891679268 hasRelatedWork W2024354894 @default.
• W2891679268 hasRelatedWork W2024899757 @default.
• W2891679268 hasRelatedWork W2037188214 @default.
• W2891679268 hasRelatedWork W2070065625 @default.
• W2891679268 hasRelatedWork W2081107160 @default.
• W2891679268 hasRelatedWork W2107361996 @default.
• W2891679268 hasRelatedWork W2137681545 @default.
• W2891679268 hasRelatedWork W2148419752 @default.
• W2891679268 hasRelatedWork W2360661457 @default.
• W2891679268 hasRelatedWork W2519430978 @default.
• W2891679268 hasRelatedWork W2600633433 @default.
• W2891679268 hasRelatedWork W2618557602 @default.
• W2891679268 hasRelatedWork W2885693740 @default.
• W2891679268 hasRelatedWork W2949127450 @default.
• W2891679268 hasRelatedWork W2949863513 @default.
• W2891679268 hasRelatedWork W2952289236 @default.
• W2891679268 isParatext "false" @default.
• W2891679268 isRetracted "false" @default.
• W2891679268 magId "2891679268" @default.
• W2891679268 workType "dissertation" @default.